Zoetis (ZTS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.75
- Estimate
- $1.51
- Surprise
- +15.8%
- Revenue (period 2026-09-30)
- $2.39B
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
Zoetis (ZTS) beat the $1.51 estimate with adjusted EPS of $1.75 — a large 15.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZTS Hold at 5.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +15.8% surprise compares with a +4.2% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Geographic: United States (54.0%)
- Concentration risk — Product: companion animal products (70.0%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $79.64
- Entry target
- $76.88
- Stop
- $71.50
At 14.7× trailing and 12.8× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
ZTS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $33.93B
- P/E (fwd)
- 12.8
- P/E (ttm)
- 14.7
- 52-week range
- $68.77–$132.49
- Off 52-week high
- 39.9%
- RSI (14)
- 51
- Volume vs avg
- 0.41×
- Score today
- 5.3/10